Bausch + Lomb Names Interim CEO, Signals Stronger 2026 Outlook
Event summary
- Thomas J. Appio appointed interim CEO of Bausch + Lomb, effective immediately, while continuing as Bausch Health CEO.
- Brent Saunders departs as Bausch + Lomb CEO after three years in the role.
- Company expects to raise full-year 2026 adjusted EBITDA guidance based on strong Q3 performance.
- Appio has led Bausch Health to 13 consecutive quarters of revenue and adjusted EBITDA growth.
The big picture
The leadership change at Bausch + Lomb comes amid a period of strong financial performance, signaling confidence in the company's growth trajectory. Appio's dual role reflects a strategic alignment between Bausch + Lomb and its parent company, Bausch Health, as they aim to capitalize on market opportunities in the eye health sector. The expected guidance upgrade underscores the company's ability to deliver sustainable growth in a competitive healthcare landscape.
What we're watching
- Leadership Stability
- Whether Appio's dual role can sustain growth momentum amid leadership transition.
- Financial Momentum
- The pace at which Bausch + Lomb can convert strong Q3 performance into full-year results.
- Strategic Focus
- How the company will balance short-term performance with long-term growth initiatives.
Related topics
